NEW YORK, December 30, 2022 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is investigating potential claims against Treace Medical Concepts, Inc. (“Treace” or the “Company”) TMCI on behalf of Treace shareholders. Our investigation concerns whether Treace has violated federal securities laws and/or engaged in other illegal business practices.

click here to take part in the action.

On November 15, 2022, Culper Research published a brief report on Treace (the “Culper Report”). The Culper report expressed the “view that Treace’s primary innovation was not any medical advances but rather aggressive reimbursement practices and misleading DTC marketing,” which the Culper report called “as problematic and self-defeating as the Insurers appear to have begun scrutinizing reimbursements for lapoplasty procedures as customer complaints mount about Treace’s misleading claims.”

As a result of this news, Treace’s stock price fell $3.57 per share, or 14.81%, to close at $20.54 per share on November 15, 2022.

If you have purchased or otherwise acquired Treace stock and have suffered a loss, are a long-term shareholder, have information, would like to learn more about these claims, or have any questions about this announcement or your rights or interests in relation to these matters, please contact us Brandon Walker or Melissa Fortunato via email at investigations@bespc.comby phone at (212) 355-4648 or by fill out this contact form. There are no costs or obligations for you.

About Bragar Eagle & Squire, PC:

Bragar Eagel & Squire, PC is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivatives and other complex litigation in state and federal courts across the country. More information about the company can be found at www.bespc.com. attorney advertising. Previous results do not guarantee…